Ivonescimab vs. Pembrolizumab in NSCLC: Author Reply

by Archynetys Health Desk

We appreciate the Correspondence from Mingyang Xue and Wenyi Jin, which raises valuable questions about the HARMONi-2 study.1

Related Posts

Leave a Comment